Kepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
BUZZ-Kepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick ** Kepler Chevreux sees the European Medtech sector recovering in 2026/2027 as regulatory uncertainty, geopolitical tensions and pricing pressure from China gradually ease and create an "attractive risk-reward profile"
** The broker initiates coverage across the diagnostic sector and assigns 'buy' ratings to BioMerieux BIOX.PA and DiaSorin DIAS.MI, while placing a 'hold' rating on Qiagen QIA.DE
** BioMerieux emerges as its top pick, due to its leadership in microbiology and molecular diagnostics, offering the best combination of quality, growth and valuation
** The broker sees in DiaSorin "the strongest medium-term growth outlook through its molecular diagnostics portfolio", believing it is underestimated by the market and could positions the company in fast-growing areas in the segment
** Qiagen remains a solid molecular franchise, Kepler Chevreux says, but it suffers from low visibility on academic and life science spending, competition for its proprietary QuantiFERON test and the upcoming CEO change
COMPANY | RATING | PT |
|---|---|---|
BioMeriuex | 'Buy' | €85 |
DiaSorin | 'Buy' | €76 |
Qiagen | 'Hold' | €34 |
(Reporting by Margaux Perrin in Gdansk)
((Margaux.Perrin@thomsonreuters.com))